REGN Stock
Regeneron Pharmaceuticals, Inc. Common Stock
—
Price
Daily closes via Alpaca (IEX); today's point is the latest trade.
Key stats
Valuation
P/E (trailing)19.8
Forward P/E13.8
Price / sales5.6
Price / book2.3
EPS (12 mo)$45.28
Dividend yield0.40%
Beta0.11
Financial health last 12 months
Revenue growth+18.6%
Earnings growth+8.4%
Gross margin86.8%
Net margin+28.5%
Return on equity15.1%
Debt / equity0.08
Hover a figure for what it means.
Analyst ratings Nov 2026 · 36 analysts
Consensus: Buy
Strong buy 8Buy 18
Hold 10Sell 0
Strong sell 0
| Month | Buy | Hold | Sell | Consensus |
|---|---|---|---|---|
| Nov 2026 | 26 | 10 | 0 | Buy |
| Oct 2026 | 26 | 11 | 0 | Buy |
| Sep 2026 | 26 | 12 | 0 | Buy |
| Aug 2026 | 26 | 11 | 0 | Buy |
Latest news
Has Vertex Stock Become A Different Bet?
Yahoo · 1d ago
Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm
Benzinga · 1d ago
Alnylam (ALNY) Stock Looks Undervalued As Shares Fell 68%
Yahoo · 2d ago
2 Growth Stocks to Buy in November Without Any Hesitation
Yahoo · 2d ago
Headlines from the last 10 days via Finnhub; links open the publisher's article.
Next earnings
No report scheduled in the next 4 months.
Past earnings moves
No tracked reports yet. TradeSphere saves the expected and actual move for every report from Nov 3, 2026 on, for stocks on the Earnings page.